Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420226 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL13343679 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL19637426 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL3571595 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL25215473 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL25418925 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL27308035 | 0.95 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL1977681 | 0.95 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL31048338 | 0.94 | HPGD (0.46) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL25156692 | 0.90 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103369-A | Pyridolactam derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 3889/4885SMN1; SMN2 4385/4885NPC1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.